Close Menu
    What's Hot

    Editor’s Letter – Volume 2, Issue 5, May 2026

    May 13, 2026

    Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

    May 13, 2026

    Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

    May 13, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Will the US Asset Intensive Life Reinsurance Market Continue Recent Growth Spurt?

      April 22, 2026

      Daiichi Life to Reinsure Whole Life Block with Prismic Life

      April 13, 2026

      Reporting Change to Provide Regulators With More Transparency into US/Offshore Asset-Intensive Life Reinsurance Treaties

      January 28, 2026

      Capital Markets Investors Could Be About to Get a Slice of UK Life Insurance Risk

      November 26, 2025

      Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

      May 13, 2026

      US Annuity Sales Notch Tenth Consecutive $100bn+ Quarter

      May 11, 2026

      Life Settlement Secondary Market Returns to Growth but Plenty of Untapped Potential Still Remains

      April 22, 2026

      EIOPA Sets Out Views on Private Equity Ownership of Life Insurers in New Consultation Paper

      March 25, 2026

      Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

      May 13, 2026
      Just Group

      Safe Computing Pension Fund Completes Bulk Purchase Annuity Buy-In With Just Group

      May 11, 2026

      Bakkavor Pension Scheme Completes Bulk Purchase Annuity Buy-In With Rothesay

      May 5, 2026
      Bank of England

      Prudential Regulation Authority Publishes New Funded Reinsurance Regulations

      April 29, 2026

      Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

      April 9, 2026

      Better Understanding of Alzheimer’s Is Improving Lives if Not Actuarial Assumptions – Yet

      March 25, 2026

      Business as Usual in UK Pension Risk Transfer Market Amid Record Low Mortality in England and Wales

      March 25, 2026

      Latest CMI Model Shows Further Rise in Cohort Life Expectancy

      March 11, 2026

      Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

      May 13, 2026

      Two Years On, PHL Variable Saga Approaches Conclusion

      May 13, 2026

      UK Equity Release Market Origination Slows To Begin 2026

      May 6, 2026

      CHIP Mortgage Trust Issues C$200m of Medium-Term Notes

      April 29, 2026

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

      May 13, 2026

      Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

      May 13, 2026

      Two Years On, PHL Variable Saga Approaches Conclusion

      May 13, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Editor’s Letter – Volume 2, Issue 4, April 2026

      April 9, 2026

      Editor’s Letter – Volume 2, Issue 3, March 2026

      March 11, 2026

      Editor’s Letter – Volume 2, Issue 2, February 2026

      February 11, 2026

      Editor’s Letter – Volume 2, Issue 1, January 2026

      January 14, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    Would SFDR Article 9 Compliance Deliver an Asset Flows Boon for EU Life Settlement Funds?

    Secondary Life Markets March 8, 2023By Greg Winterton
    Brussels
    Share
    Twitter LinkedIn Email

    Two years ago, the European Commission (EC) implemented its Sustainable Finance Disclosure Regulation (SFDR), a framework that provides a level of standardisation for investment funds with regards to the environmental, social and governance claims made by these funds domiciled in the bloc.

    The ‘dark green’ funds – ‘Article 9’ funds – are funds that deliberately have some type of sustainability as their objective and meet certain criteria. Article 8 funds are those which don’t necessarily have ESG factors as the core objective of the fund, but at the very least, they ‘do no harm’. Many large institutional investors in Europe have ESG mandates of some kind, making the Article 9 tag a competitive advantage for investment funds that meet the criteria, certainly when it comes to environmental concerns, which is where the vast majority of the EC’s efforts have focused thus far.

    Life settlement funds can’t be Article 9 funds, but that’s because the EC hasn’t laid out the rules for the social-based leg of the ESG stool – it’s only the environment pillar that has had criteria decided to date. But they do meet the criteria to market themselves as Article 8-compliant funds, for two main reasons. The first is the cash benefit provided to the policyowner at the point of sale at multiple times the surrender value of the policy; the proceeds from which can be used to fund anything ranging from medical bills to paying off a mortgage (there are no restrictions). This is seen by the industry as a benefit to thousands of American consumers each year and is something that the industry itself promotes consistently.

    The second is that life insurance companies are considered to be strong ESG-friendly counterparties. The environmental footprint of these firms is much smaller than many others, and the concept of life insurance is that it’s helping people, which is a societal positive, so the ESG ratings agencies look more favourably on life carriers versus their property and casualty cousins, which may be insuring a coal mine, or a tobacco factory, for example.

    Still, Article 8 is not Article 9. But EU lawmakers will define the requirements for funds with a focus on the social eventually, which could go some way to determining whether life settlements could qualify for Article 9 status. The challenge for the life settlement space, however, is whether it gets a seat at the table during those discussions.

    “If the regulator would accept an overall argument that we are providing capital to individuals that is higher than the surrender value which therefore creates a positive social impact – that could be accepted by the regulator as enough to qualify for Article 9,” said Rainer Gruenig, CEO at Zurich-based Plenum Investments Ltd. “But the life settlement market is smaller than many others. Therefore, we don’t have as much influence in Brussels as the traditional asset classes. We’ll have to wait to see if there is anything specific that the life settlement industry can align with to justify Article 9.”

    If life settlements don’t make the cut, does it matter? Will that impact asset flows into the space negatively? Gruenig says that Article 8 is currently sufficient for the vast majority of investors. For now ESG tends not to be the starting point for initial conversations with potential clients.

    “The conversations we have currently start with the risk-return profile, they don’t start with ESG,” he says. There’s a lot to explain about life settlements before we get anywhere near ESG, but when we do, then the social benefit of the space is always a pleasant surprise for those who are less familiar with life settlements.”

    The European life settlement market will have to wait to find out whether these funds can be ‘re-branded’ as Article 9 or not. For Gruenig, it’s a no-brainer, but whilst he doesn’t think it’ll impact asset flows, the bigger picture would be a tailwind to the space.

    “I personally believe that EU domiciled life settlement funds should be Article 9. Our industry creates a positive impact for policyowners by realising a higher cash value for their policy, and their spending creates and sustains jobs. Life Settlements thus make a small but effective contribution to solving the problems surrounding old-age poverty and the financial effects of rising life expectancies including but not limited to helping seniors to pay for their health care costs. We’re a positive business,” he said. “But while I don’t think that it would make a significant difference to allocations from investors in the short term, Article 9 compliance would at least provide us with the opportunity to be involved in the impact conversation, which is important strategically for our market.”

    2023 - March Life Settlements Longevity Risk Regulation Volume 2 Issue 3 - March 2023
    Share. Twitter LinkedIn Email

    Related Posts

    Two Years On, PHL Variable Saga Approaches Conclusion

    May 13, 2026By Greg Winterton

    Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

    May 13, 2026By Dr. Jyotsna Kamble
    Just Group

    Safe Computing Pension Fund Completes Bulk Purchase Annuity Buy-In With Just Group

    May 11, 2026By LMI Newsdesk

    UK Equity Release Market Origination Slows To Begin 2026

    May 6, 2026By LMI Newsdesk
    Latest Issue

    Too Early To Judge Impact of New Funded Reinsurance Rules on UK Pension Risk Transfer Market

    May 13, 2026

    Proprietary Reverse Mortgage Market Growth a Welcome Development for MBS Investors

    May 13, 2026

    Two Years On, PHL Variable Saga Approaches Conclusion

    May 13, 2026

    Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

    May 13, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.